139 related articles for article (PubMed ID: 25219510)
1. Structural analysis of the human fibroblast growth factor receptor 4 kinase.
Lesca E; Lammens A; Huber R; Augustin M
J Mol Biol; 2014 Nov; 426(22):3744-3756. PubMed ID: 25219510
[TBL] [Abstract][Full Text] [Related]
2. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
[TBL] [Abstract][Full Text] [Related]
3. Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.
Tucker JA; Klein T; Breed J; Breeze AL; Overman R; Phillips C; Norman RA
Structure; 2014 Dec; 22(12):1764-1774. PubMed ID: 25465127
[TBL] [Abstract][Full Text] [Related]
4. Insight into ponatinib resistance mechanisms in rhabdomyosarcoma caused by the mutations in FGFR4 tyrosine kinase using molecular modeling strategies.
Wu C; Chen X; Chen D; Xia Q; Liu Z; Li F; Yan Y; Cai Y
Int J Biol Macromol; 2019 Aug; 135():294-302. PubMed ID: 31128178
[TBL] [Abstract][Full Text] [Related]
5. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
Li SQ; Cheuk AT; Shern JF; Song YK; Hurd L; Liao H; Wei JS; Khan J
PLoS One; 2013; 8(10):e76551. PubMed ID: 24124571
[TBL] [Abstract][Full Text] [Related]
6. Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455.
Wu D; Guo M; Philips MA; Qu L; Jiang L; Li J; Chen X; Chen Z; Chen L; Chen Y
PLoS One; 2016; 11(9):e0162491. PubMed ID: 27618313
[TBL] [Abstract][Full Text] [Related]
7. FGFR4 and its novel splice form in myogenic cells: Interplay of glycosylation and tyrosine phosphorylation.
Kwiatkowski BA; Kirillova I; Richard RE; Israeli D; Yablonka-Reuveni Z
J Cell Physiol; 2008 Jun; 215(3):803-17. PubMed ID: 18186042
[TBL] [Abstract][Full Text] [Related]
8. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
9. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
Byron SA; Chen H; Wortmann A; Loch D; Gartside MG; Dehkhoda F; Blais SP; Neubert TA; Mohammadi M; Pollock PM
Neoplasia; 2013 Aug; 15(8):975-88. PubMed ID: 23908597
[TBL] [Abstract][Full Text] [Related]
10. Differential distribution of fibroblast growth factor receptors (FGFRs) on foveal cones: FGFR-4 is an early marker of cone photoreceptors.
Cornish EE; Natoli RC; Hendrickson A; Provis JM
Mol Vis; 2004 Jan; 10():1-14. PubMed ID: 14737068
[TBL] [Abstract][Full Text] [Related]
11. Biophysical characterization of drug-resistant mutants of fibroblast growth factor receptor 1.
Yoza K; Himeno R; Amano S; Kobashigawa Y; Amemiya S; Fukuda N; Kumeta H; Morioka H; Inagaki F
Genes Cells; 2016 Oct; 21(10):1049-1058. PubMed ID: 27558949
[TBL] [Abstract][Full Text] [Related]
12. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor 4 (FGFR4) is expressed in adult rat and human retinal photoreceptors and neurons.
Fuhrmann V; Kinkl N; Leveillard T; Sahel J; Hicks D
J Mol Neurosci; 1999; 13(1-2):187-97. PubMed ID: 10691305
[TBL] [Abstract][Full Text] [Related]
14. Structural study of ponatinib in inhibiting SRC kinase.
Guo M; Duan Y; Dai S; Li J; Chen X; Qu L; Chen Z; Wei H; Jiang L; Chen Y
Biochem Biophys Res Commun; 2022 Apr; 598():15-19. PubMed ID: 35151199
[TBL] [Abstract][Full Text] [Related]
15. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
16. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
Taylor JG; Cheuk AT; Tsang PS; Chung JY; Song YK; Desai K; Yu Y; Chen QR; Shah K; Youngblood V; Fang J; Kim SY; Yeung C; Helman LJ; Mendoza A; Ngo V; Staudt LM; Wei JS; Khanna C; Catchpoole D; Qualman SJ; Hewitt SM; Merlino G; Chanock SJ; Khan J
J Clin Invest; 2009 Nov; 119(11):3395-407. PubMed ID: 19809159
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
Lu X; Chen H; Patterson AV; Smaill JB; Ding K
J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors.
Liu Y; Peng X; Guan X; Lu D; Xi Y; Jin S; Chen H; Zeng L; Ai J; Geng M; Hu Y
Eur J Med Chem; 2017 Jan; 126():122-132. PubMed ID: 27750146
[TBL] [Abstract][Full Text] [Related]
19. Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4.
Pan YL; Liu YL; Chen JZ
Molecules; 2018 Mar; 23(4):. PubMed ID: 29584670
[TBL] [Abstract][Full Text] [Related]
20. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.
Ho HK; Németh G; Ng YR; Pang E; Szántai-Kis C; Zsákai L; Breza N; Greff Z; Horváth Z; Pató J; Szabadkai I; Szokol B; Baska F; Őrfî L; Ullrich A; Kéri G; Chua BT
Curr Med Chem; 2013; 20(10):1203-17. PubMed ID: 23409720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
